FITC-NYZL1分子探针标记膀胱癌患者尿脱落细胞特异性的研究

The specificity of targeting urine exfoliated cells with FITC-NYZL1

目的研究FITC-NYZL1分子探针标记尿脱落细胞的特异性,探索其在诊断和监测膀胱癌的临床应用价值。方法收集2014年8月至2015年1月山西医科大学第一医院66例膀胱癌患者尿液,选取12例膀胱炎患者和24名健康人作为对照。固相合成法制备探针FITC-NYZL1,将2h内的新鲜尿液离心、滴片,加入探针孵育,扫描激光共聚焦显微镜(LSCM)观察探针与细胞的结合率,同时取新鲜尿液进行瑞-吉染色。结果 FITC-NYZL1标记膀胱癌患者尿脱落细胞的阳性率为100%(66/66);不同临床分期患者尿脱落细胞的结合率有差异。对照组结合率很低,实验组与对照组间差异有统计学意义(P<0.001)。结论 FITCNYZL1分子探针标记结合膀胱癌细胞,特异性高,可提高膀胱癌患者尿脱落细胞的阳性率;FITC-NYZL1在分期不同的癌细胞中结合率不同,分期越高,荧光探针特异性结合率越高。FITC-NYZL1标记有望成为膀胱癌无创诊断和临床监测的新技术。

Objective To study the probe FITC-NYZL1 targeting urine exfoliated cells and its practicality in diagnosing and monitoring bladder tumors. Methods Urine samples of 66 patients with bladder cancer hospitalized during Aug. 2014 and Jan. 2015 were collected, and urine samples of 12 cystitis patients and 24 healthy people served as controls. NYZL1 was synthesized in solid state and labeled with FITC, which formed the fluorescence molecular probe. Fresh urine was sampled within 2 hours and centrifuged. The LSCM was used to observe the combination of probe after the cells were incubated with probe. At the same time, fresh urine was collected for Wright-Giemsa examination. Results FITC-NYZL1 could specifically bind to bladder cancer cells in urine, with the positive rate being 100% （66/66）. However, the percentage of specific binding in the control group was very low. Conclusions FITC-CSSPIGRHC can specifically bind to bladder cancer cells. The bind rate is different in bladder cancer cells of different stage, the higher stage, the higher sensitivity. This suggests that FITC- CSSPIGRHC may serve as a new technique for the noninvasive diagnosis and clinical monitoring of bladder tumor.